LAVIPHARM S.A. NA EO 1 Capital Reinvestment Ratio
LAVIPHARM S.A. NA EO 1 capital reinvestment ratio. LAVIPHARM S.A. NA EO 1 (BXA0) has a Capital Reinvestment Ratio of 2.08x as of December 2024, meaning it reinvests 2% of its operating cash flow (€4.64 Million) in capital expenditures (€9.64 Million). Check how aggressively does LAVIPHARM S.A. NA EO 1 reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of LAVIPHARM S.A. NA EO 1 (2021–2024)
Capital reinvestment ratio of LAVIPHARM S.A. NA EO 1 from 2021 to 2024. This chart tracks LAVIPHARM S.A. NA EO 1's Capital Reinvestment Ratio across 4 annual periods. Also explore LAVIPHARM S.A. NA EO 1 (BXA0) equity growth momentum to track the company's year-over-year net asset growth rate.
LAVIPHARM S.A. NA EO 1 Capital Reinvestment Ratio by Year (2021–2024)
LAVIPHARM S.A. NA EO 1 capital reinvestment ratio by year from 2021 to 2024. For the full cash flow conversion analysis, see BXA0 cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 2.08x | €4.64 Million | €9.64 Million | ▼ -85.4% |
| 2023 | 14.26x | €284.00K | €4.05 Million | ▲ +33.9% |
| 2022 | 10.64x | €3.35 Million | €35.62 Million | ▲ +2181.6% |
| 2021 | 0.47x | €4.11 Million | €1.92 Million | — |